公开(公告)号：US20210252109A1

公开(公告)日：2021-08-19

申请号：US17269874

申请日：2019-08-19

申请人： Centro de Ingeniería Genética y Biotecnología

发明人： Jorge Amador BERLANGA ACOSTA ,  Gerardo Enrique GUILLÉN NIETO ,  Diana GARCIA DEL BARCO HERRERA ,  Francisco HERNÁNDEZ BERNAL ,  Sonia GONZALEZ BLANCO ,  Raimundo UBIETA GÓMEZ

IPC分类号： A61K38/25 ,  A61P9/10 ,  A61K9/00

摘要： The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.

公开(公告)号：US20210196793A1

公开(公告)日：2021-07-01

申请号：US17269788

申请日：2019-08-16

申请人： CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA

发明人： Diana GARCIA DEL BARCO HERRERA ,  Gerardo Enrique GUILLÉN NIETO ,  Mariela VAZQUEZ CASTILLO ,  Francisco HERNÁNDEZ BERNAL ,  Tatiana ZALDIVAR VAILLANT ,  Pablo Arsenio DIAZ REYES ,  ldania Caridad BALADRON CASTRILLO ,  Vladimir Armando BESADA PÉREZ ,  Sonia GONZALEZ BLANCO ,  Jorge Amador BERLANGA ACOSTA ,  Héctor Manuel PÉREZ SAAD

IPC分类号： A61K38/18 ,  A61P25/00 ,  A61K38/27

摘要： The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The efficacy of the pharmaceutical combination has a broad therapeutic window: it is independent of whether the pharmacological intervention occurs in the first or further hours after the brain damage, which broadens the therapeutic window.

公开(公告)号：US20240139105A1

公开(公告)日：2024-05-02

申请号：US18274955

申请日：2022-01-27

申请人： CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA

发明人： Jesús Hector SANTANA MILIAN ,  Francisco HERNANDEZ BERNAL ,  Sonia GONZALEZ BLANCO ,  Yasser ZARATE RIVERA ,  Mercedes Dania BACARDÍ FERNÁNDEZ ,  Diana GARCIA DEL BARCO HERRERA ,  Yaima GONZÁLEZ GONZÁLEZ ,  Raúl Fidel CASTRO ODIO ,  Jorge Amador BERLANGA ACOSTA ,  Gerardo Enrique GUILLEN NIETO ,  Juan VALIENTE MUSTELIER

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K9/19 ,  A61K38/08 ,  A61K47/12 ,  A61K47/26 ,  A61P9/10

CPC分类号： A61K9/08 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/08 ,  A61K47/12 ,  A61K47/26 ,  A61P9/10

摘要： Pharmaceutical composition comprising growth-hormone releasing peptide 6 (GHRP-6), tartrate buffer at pH 5.0-6.0, and trehalose as stabilizing agent, as well as the use of said composition for the manufacture of a medicament. The invention also provides a kit of parts comprising said pharmaceutical composition and a method of treatment of an individual in need thereof, which entails the administration of a therapeutically effective amount of the pharmaceutical composition comprising of GHRP-6, tartrate buffer at pH 5.0-6.0 and trehalose.